New Frontline Targets Transforming Upper GI Cancer Care
Early ASCO GI 2026 data spotlight major advances in HER2-positive and CLDN18.2-expressing upper GI cancers, with bispecific HER2 targeting showing meaningful progression-free and overall survival...
